Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experience with public-private partnerships

EMBO Reports

Volumn 4, Issue SPEC. ISS., 2003, Pages

  Ridley, Robert G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; ARTEMISININ; ARTESUNATE; DIETHYLCARBAMAZINE; EFLORNITHINE; IVERMECTIN; MELARSOPROL; MILTEFOSINE; PAROMOMYCIN; PYRONARIDINE; SURAMIN; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ARTESUNATE PLUS PYRONARIDINE; CHLORPROGUANIL PLUS DAPSONE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CHEMOTHERAPY; CLINICAL STUDY; DECISION MAKING; DISEASE CONTROL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG RESEARCH; GOOD CLINICAL PRACTICE; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; MALARIA; ONCHOCERCIASIS; PRIORITY JOURNAL; SCHISTOSOMIASIS; SIDE EFFECT; TROPICAL DISEASE; VISCERAL LEISHMANIASIS; DEVELOPING COUNTRY; DRUG DEVELOPMENT; DRUG INDUSTRY; KNOWLEDGE; MEDICAL EXPERT; NEGLECTED DISEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PUBLIC-PRIVATE PARTNERSHIP; WORLD HEALTH ORGANIZATION;

ARTESUNATE;

EID: 0037777624     PISSN: 1469221X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.embor.embor858     Document Type: Article

References (10)

1. Bhattacharya, S. (2002) Capacity building for clinical trials: the investigator's perspective. TDR News, 69, November (see www.who.int/tdr).
2. Lang, T. & Greenwood, B. (2003) The development of Lapdap, an affordable new treatment for malaria. Lancet Infect. Dis., 3, 162-167.
3. Morel, C.M. (2000) Reaching maturity - 25 years of the TDR. Parasitol. Today, 16, 522-528.
4. Pecoul, B., Chirac, P., Trouiller, P. & Pinel, J. (1999) Access to essential drugs in poor countries: a lost battle? JAMA, 281, 361-367.
5. Remme, J.H. et al. (2002) Strategic emphases for tropical diseases research: a TDR perspective. Trends Microbiol. 10, 435-440.
6. Ridley, R.G. (2000) Medicines for Malaria Venture. Medicus Mundi, 78, October.
7. Ridley, R.G. (2002) Medical need, scientific opportunity and the drive for antimalarial drugs. Nature, 415, 686-693.
8. Sundar, S. et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med., 347, 1739-1746.
9. Trouiller, P. et al. (2001) Drugs for neglected diseases: a failure of the market and a public health failure? Trop. Med. Int. Health, 6, 945-951.
10. Winstanley, P. (2001) Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop. Med. Int. Health, 6, 952-954.